UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) ...

Levicept has presented new data from its phase 2 trial of LEVI-04 at the European Congress of Rheumatology (EULAR 2025). The ...

Argenx has presented positive phase 2 results for efgartigimod in myositis and Sjogren’s disease at EULAR 2025. The company ...

In a move to progress treatment efficacy, oncologists widely agree that, in the future, cancer treatments will become ...

The European Migraine and Headache Alliance (EMHA) has urged EU policymakers to include migraine in the forthcoming ...

The PharmaTimes Clinical Researcher of the Year – The Americas 2025 Awards offer an unparalleled opportunity to showcase your ...

Birmingham spin-out Linear Diagnostics has secured £1m funding to advance a rapid test for sexually transmitted infections ...

Santen has announced that the European Commission has granted market authorisation for Ryjunea, a low-dose atropine eye drop ...

Tagomics has been awarded £860k in funding from Innovate UK’s Biomedical Catalyst programme to develop a novel diagnostic ...

Tozaro has announced the appointment of Dr Jason Slingsb y as Chief Executive Officer. Jason will lead the company’s ...

Sogroya acts as a replacement for endogenous growth hormone and is administered once a week to support growth in children ...